Drugs / MK-1029
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT01370317 | Jun → Dec 2011 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01343407 | Apr 2011 → Jan 2012 | asthma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 23 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT02720081 | May 2016 → Aug 2017 | asthma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT01656395 | Aug 2012 → Jun 2014 | asthma | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2 | NCT01624974 | Aug 2012 → May 2014 | asthma | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02720081 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL3545031 ↗ |
| Route | Oral | “Five (5) X 100 mg capsules, orally, once daily for 28 days” NCT01370317 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL3545031 ↗ |